Tofacitinib for the Treatment of Pyoderma Gangrenosum
Open Access
- 1 April 2019
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 17 (5) , 991-993
Abstract
No abstract availableKeywords
Funding Information
- Crohn's and Colitis Foundation (568735)
This publication has 7 references indexed in Scilit:
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2019
- Pyoderma Gangrenosum: A Review for the GastroenterologistInflammatory Bowel Diseases, 2018
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2017
- JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future ProspectsDrugs, 2017
- JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2016
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trialThe Lancet, 2015
- Potential role for SNAIL family transcription factors in the etiology of Crohnʼs disease-associated fistulaeInflammatory Bowel Diseases, 2011